Purisys Eyes Importing Marijuana Extracts – Public Input Sought
Published Date: 3/13/2026
Notice
Summary
Purisys, LLC wants to become an official importer of certain controlled substances like marijuana and its extracts. People and companies involved can share their thoughts or ask for a hearing by April 13, 2026. This move could affect businesses handling these substances and might change how imports are managed, but no costs are mentioned yet.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Opium Imports for API Manufacturing
Purisys plans to import Opium, Raw (9600), Opium, Powdered (9639), and Opium, Granulated (9640) specifically to manufacture an Active Pharmaceutical Ingredient (API) only for distribution to its customers. The company states these imports are intended solely for API manufacture.
Bulk Manufacture Inputs: Phenylacetone & Poppy Straw
Purisys plans to import Phenylacetone (8501) and Poppy Straw Concentrate (9670) to bulk manufacture other controlled substances for distribution to its customers. The company explicitly states these imports are for bulk manufacture.
No Import of Finished Dosage Forms Allowed
The notice states that approval will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. Registrants must have business activity consistent with 21 U.S.C. 952(a)(2) to receive authorization.
Application to Import Many Controlled Drugs
Purisys, LLC filed an application on February 4, 2026 to be registered as an importer of a list of controlled substances (including Marihuana Extract 7350, Marihuana 7360, Tetrahydrocannabinols 7370, and multiple Schedule II drugs such as Methadone 9250 and Thebaine 9333). The notice lists each drug code and schedule and is open for comments or hearing requests through April 13, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2026-04969 — Bulk Manufacturer of Controlled Substances Application: Stepan Company
Stepan Company wants to get official permission to make large amounts of cocaine and ecgonine, which are controlled substances. This affects other manufacturers and customers who use these drugs, and people have until May 12, 2026, to share their thoughts or ask for a hearing. No big money changes are mentioned, but this move could impact how these substances are made and sold.
Next: 2026-04971 — Bulk Manufacturer of Controlled Substances Application: Pisgah Laboratories Inc
Pisgah Laboratories Inc wants to become a big-time maker of certain controlled drugs, including some strong medicines and research chemicals. People and companies affected can share their thoughts or ask for a hearing by May 12, 2026. This move could impact drug supply and regulation, but no costs or deadlines beyond the comment period are set yet.